Risk Factors for Immune Checkpoint Inhibitor–Mediated Cardiovascular Toxicities

被引:0
作者
Laura I. Yousif
Elles M. Screever
Daniëlle Versluis
Joseph Pierre Aboumsallem
Stefan Nierkens
Olivier C. Manintveld
Rudolf A. de Boer
Wouter C. Meijers
机构
[1] Erasmus University Medical Center,Department of Cardiology, Thorax Center
[2] Utrecht University,Graduate School of Life Science
[3] Utrecht University,Center for Translational Immunology
[4] University Medical Center Utrecht,undefined
[5] Princess Máxima Center for Pediatric Oncology,undefined
来源
Current Oncology Reports | 2023年 / 25卷
关键词
ICI; Myocarditis; Pericarditis; Vasculitis; Risk factors;
D O I
暂无
中图分类号
学科分类号
摘要
引用
收藏
页码:753 / 763
页数:10
相关论文
共 285 条
[11]  
Salem JE(2017)Primary, adaptive, and acquired resistance to cancer immunotherapy Cell 168 707-34
[12]  
Manouchehri A(2018)Mechanisms of resistance to PD-1 and PD-L1 blockade Cancer J 24 47-868
[13]  
Moey M(2021)Cardiotoxicity associated with immune checkpoint inhibitor therapy: a meta-analysis Eur J Heart Fail 23 1739-2194
[14]  
Mahmood SS(2016)Fulminant myocarditis with combination immune checkpoint blockade N Engl J Med 375 1749-228
[15]  
Fradley MG(2011)PD-1 and LAG-3 inhibitory co-receptors act synergistically to prevent autoimmunity in mice J Exp Med 208 395-2051
[16]  
Cohen JV(2012)Immune inhibitory molecules LAG-3 and PD-1 synergistically regulate T-cell function to promote tumoral immune escape Cancer Res 72 917-903
[17]  
Johnson DB(2022)Relatlimab and nivolumab versus nivolumab in untreated advanced melanoma N Engl J Med 386 24-4409
[18]  
Sullivan RJ(2021)Pericardial disease in patients treated with immune checkpoint inhibitors J Immunother Cancer 9 e002771-520
[19]  
Menzies AM(2022)Cardiac toxicity associated with immune checkpoint inhibitors: a systematic review Int J Mol Sci 23 10948-1776
[20]  
Yousif LI(2020)Myocardial vasculitis associated with the immune checkpoint inhibitor pembrolizumab JACC Case Rep 2 1937-12